Researchers at Vanderbilt University Medical Center have relieved symptoms in a mouse model of Rett syndrome with a drug-like compound that works like the dimmer switch in an electrical circuit.
The finding, reported this week in the journal Human Molecular Genetics, suggests a potential new way to treat the rare neurodevelopmental disorder, which occurs predominantly in females, as well as more common forms of autism spectrum disorder.
Further study is needed before this approach can be tested in patients, but animal work from other groups suggests that symptoms in Rett syndrome are reversible, said senior author Colleen Niswender, Ph.D., associate professor of Pharmacology and director of Molecular Pharmacology in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD).
Rett syndrome patients exhibit a constellation of symptoms, including verbal and nonverbal communication deficits, difficulty walking, progressive developmental regression, epilepsy and intellectual disability. The hallmark symptom is repetitive hand movements such as wringing, washing, clapping or tapping.
Most cases of Rett syndrome occur spontaneously from random mutations in the MECP2 gene, which results in disruptions in neurotransmission, including signals mediated by the excitatory transmitter glutamate. A related genetic disorder, termed MECP2 Duplication syndrome, results from overexpression of the MeCP2 protein and is found predominantly in young boys.
The researchers used a mouse model in which MECP2 was “knocked out,” resulting in Rett syndrome-like symptoms. Expression of the metabotropic glutamate receptor 5 (mGlu5), which is important in transmitting nerve signals in the brain, was reduced in brain areas of these mice.
The investigators also found reduced levels of mGlu5 expression in autopsy samples from the brains of Rett syndrome patients, suggesting that the animal work may translate to the clinical population.
They then tested a compound, developed at Vanderbilt, called a positive allosteric modulator or PAM that, like a dimmer switch, “turns up” the activity of mGlu5 when glutamate binds to it.
Animals treated with the compound showed improved motor performance and reduced Rett syndrome-like symptoms, including repetitive clasping of their hind claws.
Previous studies have suggested that enhancing excitatory neurotransmission may increase an already high risk of seizures in Rett patients, but in the current study, seizure occurrence did not increase, even after multiple weeks of chronic dosing with the PAM.
This may be because the compound acts on only a subset of mGlu5-mediated signaling pathways, leaving others unaffected.
“Our work demonstrates that potentiating the activity of mGlu5 can rescue several deficits commonly found in mouse models of Rett syndrome,” said the paper’s first author, Rocco Gogliotti, Ph.D., a postdoctoral fellow in the VCNDD.
“Importantly, by integrating recent advancements in mGlu5 pharmacology into the drug development process, we were able to test the efficacy of our novel compound in a mouse model without observing negative side effects, such as seizures, that have been historically associated with this target,” he said.
Disease progression – and mGlu5 expression – change through time in MeCP2-deficient mice. “A very careful dissection of the time course of the disease is required before modulators of excitatory transmission can be advanced to clinical studies,” Niswender said.
“It may be that early stages of Rett syndrome will need to be treated differently than late-stage disease,” she said.
The Latest on: Rett syndrome
- US Patent Issued for Anavex 2-73 for Treatment of Neurodevelopmental Disorders, Including MSon January 10, 2020 at 11:23 am
Anavex Life Sciences has received a U.S. patent covering the use of Anavex 2-73 (blarcamesine) for the treatment of several neurodegenerative and neurodevelopmental conditions, including multiple ...
- Kidderminster mother's joy as disabled daughter 'given voice'on January 8, 2020 at 10:23 am
Judith Worrall said daughter Pauline lost her speech aged two following a "devastating diagnosis" of Rett syndrome, a rare neurological disorder. Mrs Worrall said the 36-year-old has been increasingly ...
- Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosison January 8, 2020 at 4:33 am
NEW YORK, Jan. 08, 2020 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated.
- Coronado family champions accessible playgroundson January 6, 2020 at 5:12 am
All 2-year-old Abby Fabiszak wanted was for her older sister, Chelsea, to swing with her. But it was impossible. Chelsea, then 12, had been diagnosed with Rett syndrome, a rare genetic brain disorder ...
- Time-delimited signaling of MET receptor tyrosine kinase regulates cortical circuit development and critical period plasticityon January 3, 2020 at 6:36 am
A protein that may serve such a function is the MET receptor tyrosine kinase, which is tightly regulated developmentally in rodents and primates, and exhibits reduced cortical expression in autism ...
- Ontario family pleads for funding to buy device to help daughter, 2, with Rett Syndromeon December 16, 2019 at 2:01 pm
When it’s one in 10,000 you really don’t think it’s going to happen to you,” said Stephanie. Mackenzie was diagnosed with Rett Syndrome in August, a rare disease that attacks a child’s motor skills.
- Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndromeon November 19, 2019 at 5:29 am
We are looking forward to the results of our Sarizotan Treatment of Apneas in Rett Syndrome (STARS) study, a study to evaluate the efficacy, safety and tolerability of sarizotan in patients with Rett ...
- Studying Astrocytes in Rett Syndromeon November 12, 2019 at 2:46 am
This article offers a comprehensive description of the role played by astrocytes in Rett Syndrome. Rett Syndrome, a neurodevelopmental disorder, affects around 1 in 12,000 girls. It is characterized ...
- Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndromeon November 6, 2019 at 4:02 am
Rett syndrome, a rare genetic neurological disorder that afflicts mostly girls, is caused by a genetic defect associated with severe physical and cognitive impairments. The study evaluated doses of ...
- Newron Initiates Outreach on First Global Rett Syndrome Burden of Illness Survey in Collaboration with the Rett Communityon October 29, 2019 at 10:05 am
Rett syndrome is a severe neuro-developmental orphan disease with no approved treatment options and overwhelmingly affects girls starting at a very young age. The survey outreach, to launch November 1 ...
via Google News and Bing News